NCM·Healthcare·$168M·#187 / 520 in Healthcare
IMDX Insight Molecular Diagnostics I
54SPECULATIVE
CATEGORY BREAKDOWN
GROWTH100
QUALITY48
STABILITY41
VALUATION0
GOVERNANCE68
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+115.6%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
56.7%
80
> 50% strong
Cash Runway
Months of cash at current burn rate
6 months
11
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-11.1%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
41.3x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-639
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
20.0%
85
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+12.5%
33
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE IMDX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when IMDX's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.